Compare AKAN & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKAN | PRFX |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.6M |
| IPO Year | 2021 | 2020 |
| Metric | AKAN | PRFX |
|---|---|---|
| Price | $0.64 | $2.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 123.6K | ★ 344.5K |
| Earning Date | 04-29-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $0.58 |
| 52 Week High | $9.29 | $3.71 |
| Indicator | AKAN | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 59.08 |
| Support Level | $0.51 | $1.28 |
| Resistance Level | $1.12 | $2.95 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 32.73 | 84.31 |
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.